

17 May 2024 | Analysis

Pink Sheet Podcast: BIOSECURE Act Advances, Trial Diversity Sticks, Platform Principles Without Designation

by Derrick Gingery

Pink Sheet editors and reporter consider the implications of the BIOSECURE Act as it advances through a House committee, whether industry would improve clinical trial diversity with tougher enforcement of the regulation, as some have suggested, and the FDA's use of platform technology ideas for gene therapies not participating in the program.

Pink Sheet Executive Editor Derrick Gingery, Senior Writer Sarah Karlin-Smith, and Interim Editor in Chief Nielsen Hobbs discuss the implications of the BIOSECURE Act on the pharma industry in the US and China now that the bill that would restrict US government contracting with "biotechnology companies of concern," as well as the other companies that contract with them, has cleared the House Oversight and Accountability Committee (:30). They also consider some in industry pleading for tougher US Food and Drug Administration enforcement of clinical trial diversity regulations (22:26), as well as the agency's use of platform technology designation principles for products that do not qualify for the designation (33:07).

Click here to explore this interactive content online

More On These Topics From The Pink Sheet

- <u>As Biosecure Bill Mores Forward, Clock Ticking For Industry To Move Away From Chinese CDMOs</u>
- <u>BIOSECURE Act Update Offers Biotech Companies Eight Years to Divest Contracts With Firms Of 'Concern'</u>
- Senate Work On Biosecurity Issues Continues Even As House Is Current Focus Of Legislative

PINK SHEET CITELINE REGULATORY

<u>Activity</u>

- <u>US FDA Asked To Tighten China Risk Control By Legislators As Markup Looms</u>
- <u>'Do It Or We're Not Going To Approve Your Drug:' Industry Reps Ask FDA For Trial Diversity Sticks</u>
- <u>US FDA Using Platform Ideas Outside Of Formal Designations To Speed Cell and Gene Approvals</u>

This and other podcasts are available on the *Pink Sheet podcast page*, as well as the *Citeline* channel on *Apple Podcasts*, *Google Podcasts*, *SoundCloud*, *TuneIn* and *Spotify Podcasts*, and via smart speakers if one of these platforms has been set up as your default podcast provider.